| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President &CEO
2 companies
Bermingham Nessan serves as a President &CEO at NTLA and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 5 sells. Those positions are worth an estimated $6.0M at current prices.
The biggest single holding is NTLA (~$5.5M) as President &CEO. The recent filings there lean toward selling, a net 336,783 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2017 | NTLA Intellia Therapeutics, Inc. | President &CEO | Sell | 336,783 | $20.78 | $7,000,019.24 | -10.2% |